Bradley Foster & Sargent Inc. CT Reduces Stock Position in RxSight, Inc. (NASDAQ:RXST)

Bradley Foster & Sargent Inc. CT lowered its stake in RxSight, Inc. (NASDAQ:RXST) by 2.1% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 25,270 shares of the company’s stock after selling 542 shares during the quarter. Bradley Foster & Sargent Inc. CT owned 0.07% of RxSight worth $1,520,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in RXST. CWM LLC grew its position in shares of RxSight by 727.5% during the 2nd quarter. CWM LLC now owns 422 shares of the company’s stock valued at $25,000 after acquiring an additional 371 shares during the period. Quest Partners LLC bought a new position in RxSight in the 2nd quarter worth $41,000. Larson Financial Group LLC bought a new position in RxSight in the 1st quarter worth $51,000. RiverPark Advisors LLC raised its holdings in RxSight by 361.4% in the 1st quarter. RiverPark Advisors LLC now owns 3,082 shares of the company’s stock worth $159,000 after purchasing an additional 2,414 shares during the period. Finally, Amalgamated Bank raised its holdings in RxSight by 7.7% in the 4th quarter. Amalgamated Bank now owns 4,148 shares of the company’s stock worth $167,000 after purchasing an additional 298 shares during the period. Hedge funds and other institutional investors own 78.78% of the company’s stock.

Wall Street Analyst Weigh In

RXST has been the topic of a number of recent research reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $66.00 target price on shares of RxSight in a report on Friday, September 13th. Wells Fargo & Company decreased their target price on RxSight from $68.00 to $54.00 and set an “overweight” rating on the stock in a report on Tuesday, August 6th. Stifel Nicolaus decreased their target price on RxSight from $70.00 to $65.00 and set a “buy” rating on the stock in a report on Tuesday, August 6th. BTIG Research raised their price target on RxSight from $72.00 to $73.00 and gave the company a “buy” rating in a report on Monday, July 15th. Finally, Oppenheimer decreased their price target on RxSight from $72.00 to $65.00 and set an “outperform” rating on the stock in a report on Tuesday, August 6th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $60.14.

Insider Activity

In other news, CFO Shelley B. Thunen sold 10,000 shares of the firm’s stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $58.61, for a total transaction of $586,100.00. Following the completion of the transaction, the chief financial officer now owns 13,938 shares in the company, valued at $816,906.18. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, CFO Shelley B. Thunen sold 10,000 shares of RxSight stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $58.61, for a total value of $586,100.00. Following the completion of the transaction, the chief financial officer now owns 13,938 shares in the company, valued at $816,906.18. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Ilya Goldshleger sold 9,000 shares of RxSight stock in a transaction dated Monday, August 5th. The stock was sold at an average price of $39.25, for a total value of $353,250.00. Following the completion of the transaction, the insider now owns 42,246 shares of the company’s stock, valued at approximately $1,658,155.50. The disclosure for this sale can be found here. Company insiders own 9.36% of the company’s stock.

RxSight Stock Down 3.5 %

NASDAQ:RXST opened at $54.16 on Thursday. The stock has a market cap of $2.00 billion, a PE ratio of -42.98 and a beta of 1.22. The business’s 50-day simple moving average is $50.73 and its two-hundred day simple moving average is $53.97. RxSight, Inc. has a 52 week low of $20.66 and a 52 week high of $66.54.

RxSight (NASDAQ:RXST) last issued its quarterly earnings data on Monday, August 5th. The company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.06. The firm had revenue of $34.89 million during the quarter, compared to analyst estimates of $32.33 million. RxSight had a negative return on equity of 19.33% and a negative net margin of 31.92%. The business’s quarterly revenue was up 67.6% compared to the same quarter last year. During the same quarter last year, the business posted ($0.40) earnings per share. Sell-side analysts anticipate that RxSight, Inc. will post -0.81 earnings per share for the current fiscal year.

RxSight Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.